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Abstract.  The vacuolar protease B of Saccharomyces 
cerevisiae is a  subtilisin-like protease encoded by the 
PRB1 gene. Antibodies raised against a  synthetic pep- 
tide and an Escherichia  coli-derived  PRB1 open read- 
ing frame (ORF) protein cross-react with authentic 
protease B  from yeast. By using these antibodies, the 
posttranslational biosynthetic pathway of protease B 
has been elucidated. Preproprotease B is a  76-kD un- 
glycosylated precursor that enters the endoplasmic 
reticulum (ER),  where it receives one asparagine- 
linked (Asn-linked) and an undetermined number of 
non-Asn-linked carbohydrate side chains. The large 
glycosylated intermediate is proteolytically processed 
to a  39-kD form before exiting the ER.  In the Golgi 
complex, the 39-kD form becomes 40 kD, due to 
elaboration of the Asn-linked side chain.  The carboxy- 
terminal end of the 40-kD proprotease B undergoes 
protease A-mediated processing to a  37-kD  intermedi- 
ate, which in turn is quickly processed to 31-kD  ma- 
ture protease B. The ultimate processing step removes 
a peptide containing the Asn-linked chain; mature PrB 
has only non-Asn-linked carbohydrate. 
T  nF. lysosome-like vacuole of the yeast Saccharomyces 
cerevisiae contains several  hydrolytic activities,  in- 
cluding protease A (PrA),~ protease B (PrB), carbox- 
ypeptidase Y (CpY), a 600-kD aminopeptidase, a repressible 
alkaline phosphatase, and at least one RNase (39, 65). In all 
cases studied to date, these hydrolases are synthesized as in- 
active glycoprotein precursors  (reviewed in reference 28) 
that require the PEP4 gene product, protease A, for activa- 
tion (2, 28, 66).  Vacuolar hydrolases may be thought of as 
internally secreted  proteins,  as  they traverse the  ER and 
Golgi apparatus en route to the vacuole. Mutations that block 
transport from the ER or Golgi apparatus affect internally 
and externally secreted proteins equally (31, 57). 
Some preliminary work on the structure of PrB and its 
precursors has been reported. In kinetic experiments using 
a 20-min pulse of [35S]methionine, Mechler et al. (43) iden- 
tiffed a 42-kD precursor of PrB that is subsequently processed 
to the mature form. The relative molecular mass of the pre- 
cursor was 3 kD smaller in tunicamycin-treated  cells, but the 
relative molecular mass of the mature protease was unaf- 
fected (43). This kinetic precursor had the same relative mo- 
lecular mass as the zymogen form of protease B observed to 
accumulate in a pep4 mutant (44).  Mature protease B has 
been reported to be a glycoprotein that contains "no more 
than 0.5%" carbohydrate (61). A  different group reported 
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PrB to be a 33-kD glycoprotein with 8-9%  neutral sugars 
and 1.5 % amino sugars (32).  The neutral/amino sugar ratio 
was suggestive of an Asn-linked carbohydrate moiety. 
We recently reported the cloning and sequencing of PRB1 
and also the purification and amino-terminal sequence of 
PrB (46, 47).  Unexpectedly, analysis of the PRB1 DNA se- 
quence showed an open reading frame (ORF) of 635 codons 
that would give rise to a primary translation product with a 
predicted (unglycosylated) Mr of 69.6 kD (47).  The portion 
of the deduced amino acid sequence encoding mature PrB 
showed significant sequence similarity with members of the 
subtilisin family of proteases.  Comparison of the deduced 
amino acid sequence  and the amino-terminal protein  se- 
quence with the reported relative molecular mass of the ma- 
ture and zymogen forms of PrB, as well as the sequences of 
the highly conserved subtilisins, led us to propose a model 
for the  processing  pathway  for  PrB  (47).  The  proposed 
model  stated that the entire  ORF  was  translated and the 
resulting polypeptide received one or two Asn-linked and an 
undetermined number of non-Asn-linked side chains for a 
final molecular mass of ~,75 kD. A protease other than PrA 
was responsible for cleaving 75-kD proPrB to generate a 44- 
kD protein that is identical to the zymogen form and has the 
same amino terminus as mature PrB. In the vacuole, PrA was 
responsible for a  carboxy-terminal cleavage that generated 
mature PrB.  Support for this model was presented by us at 
the June, 1987 Yeast Genetics and Molecular Biology meet- 
ing,  2 and by others (42). 
In this paper, we describe the isolation of antibodies that 
react with PrB and the use of these antibodies to elucidate 
2. The species of PrB antigen found in glsl, alg6, secl8, and pep4 mutants 
and the glsl pep4 and alg6 pep4 double mutants were presented. 
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Name assigned 
Strain number  Genotype  by donor 
BJ52 
BJ1983 
BJ1984 
BJ2159 
BJ2160 
BJ2388 
BJ2390 
BJ2589 
BJ2590 
BJ2607 
BJ3044 
BJ3368 
BJ3369 
BJ3493 
BJ3496 
BJ3622 
BJ3629 
BJ3630 
BJ3631 
BJ3632 
BJ3638 
BJ3655b 
BJ3656 
BJ3657 
BJ3658 
BJ3748 
BJ3944 
BJ3947 
BJ4378 
BJ3192 
BJ3655a 
MATc~ prbl-628 s126 trpl 
MATs trplo 
MATer pep4-3 trplo 
MATa see7-1 
MATa secl4-1 
MATs sec53-6 
MATs sec59-1 
MATa ade2-101o alg5-1  ura3-52 
MATa ade2-101o alg6-1  ura3-52 
MATa leu2 prbl-l122  trplo ura3-52 
MATa can1 lys2-80A prbl-A1.6 ura3-52 
MATs argl kex2,l his7 ural  [KIL-Kt] 
MATa ade2 kexl-1 thrl Arg  ÷ [KIL-K,] 
MATs his3-A200 pep4::HlS3 trpl-AlO1 ura3-52 
MATa his3-A200  lys2-8Ola pep4::HlS3 ura3-52 
MATc~ glsl-1 secl8-1 
MATa ade2-101o trpl-Al01 ura3-52 
MATa ade2-101o alg6-1  his3-A200 pep4::HIS3  ura3-52 
MATs alg6-1  ura3-52 
MATs his3-A200 pep4::HlS3 trpl-Al01 ura3-52 
MATa mnnl-3 
(MATeO* pep4::H1S3 secl8-1 (HIS3?) 
(MATeO glsl-I pep4::H1S3 secl8-1 (HIS3?) 
MATa his3-A200  lys2-80A ura3-52 
MATa glsl-1 HIS3 lys2-8Ola ura3-52 
MATa secl8-1 ura3-52 
MATs his4 1eu2-3,-112 see62-1 ura3-52 
MATs his4 leu2-3,-112  see61-1  trpl ura3-52 
MATs his4-519  1eu2-3,-112 secll-7 ura3-52 
E.  coli JM83 carrying pUCPRBl§ 
E.  coli W3110  [laclq] carrying pUCPRBIAH 
Is trpl] 
[SF294-2B]II 
[HMSF169]II 
[HMSF331]II 
[SF402-3B]II 
[73-2D]¶ 
[1004-4A]¶ 
[TRPRB39A] 
[XCMM42-1A] 
[79]** 
192A1  *  * 
[XCMM66-8A] II 
[XCMM66-8B] 
[XCMM66-8C] 
[XCMM66-8D] 
[XW451-3B]** 
[XCMM71-10A] 
[XCMM71-10B] 
[XCMM71-10C] 
[XCMM71-10D] 
[NY431 ] §§ 
lRDM50-94Clll 
[RDM7-4B]II 
[PBY408A]II 
* All strains were derived in this lab except where noted. Strains bearing, or derived from strains b~aring, glycosylation, killer expression, or secretory mutations 
are not necessarily congenic to X2180, the genetic background of nearly all other strains from this laboratory. 
* Genotypes presented in parentheses are inferred or,  when presented in conjunction with a ?, unknown. 
§ Obtained from U. Schmeissner of Biogen SA, Geneva, Switzerland. 
II Obtained from R. Schekman, P. Novick, T.  Stevens, R. Deshaies, P. B6hini, University of California, Berkley. 
¶ Obtained from T.  Huffaker and P. Robbins, Massachusetts Institute of Technology, Cambridge, MA. 
** Obtained from R. Wickner,  National Institutes of Health. 
*:~ Obtained from C. Ballou, University of California, Berkley. 
§§ Obtained from P. Novick, Yale University, New Haven, CT. 
the posttranslational  biosynthetic pathway for PrB. The pro- 
posed processing model (47) has been essentially validated, 
and  additional  unanticipated  details  were  discovered.  At 
least three proteolytic processing steps are required for PrB 
maturation.  The precursors have both Asn-linked and non- 
Asn-linked carbohydrate moieties, but mature PrB has only 
non-Asn-linked carbohydrate.  Kinetically, preproprotease B 
appears  to be posttranslationally  rather than cotranslation- 
ally glycosylated. The processing step that generates the ma- 
ture amino terminus of PrB occurs in the ER. The structures 
of some of the intermediates in the PrB processing pathway 
raise important  questions about secretory protein localiza- 
tion and processing. 
Materials and Methods 
Chemicals and Media 
Azocoll, Hide Powder Azure, keyhole limpet hemocyanin (KLH),  and iso- 
propylthiogalactoside  (IPTG) were from Calbiochem-Behring Corp., San 
Diego, CA, m-maleimidobenzoyl-N-hydroxysuccinimide  ester (MBS) from 
Pierce Chemical Co., Rockford, IL, and glass beads, 0.44-0.46 mm diam, 
from Thomas Scientific, Philadelphia, PA. Protein dye reagent,  SDS, Atti- 
gel  10, and Atti-gel  15 were purchased from Bio-Rad Laboratories,  Rich- 
mond, CA, the C18 HPLC column (600RP) from Alltech, Inc., Deerfield, 
IL, TLC plates from Analtech, Newark, DE, Sephadex G-25 from Pharma- 
cia Inc., Piscataway, NJ, lysozyme, ampicillin, Freund's adjuvants, Ponceau 
S stain,  Tween-20,  protein A-Sepharose 4B, and Alcian Blue 8GX from 
Sigma Chemical Co., St. Louis, MO. Nitrocellulose  for immunoblots (0.45 
#m) was from Schleicher & Schuell, Keene, NH. Media supplies were from 
Difco Laboratories Inc., Detroit, MI, NP-40 from LKB Instruments Inc., 
Gaithersburg,  MD, proteinase K and subtilisin from Boehringer Mannheim 
Diagnostics  Inc., Indianapolis,  IN, Vectastain kits from Vector Laborato- 
ries, Inc., Burlingame,  CA, ENHANCE from New England Nuclear,  Bos- 
ton, MA, AUTOFLUOR from National Diagnostics,  Manville,  NJ. Car- 
rier-free [35S]sulfate and [35S]methionine, 1,000 Ci/mmol (Trans35S label), 
were purchased from ICN Biomedicals Inc., Irvine, CA. Anti-PrA antibod- 
ies were raised in this laboratory by Dr. Martha Aynardi and Guy Bennardo. 
Purified extracellular protease from Neurospora crassa and antiprotease an- 
tibodies were the kind gift of Dr. George Marzluf, Ohio State University, 
Columbus,  OH.  Anti-CpY antibodies were  the kind gift of Dr3. Tom 
Stevens and Randy Schekman, University  of California, Berkeley, CA. 
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Relevant strains and their genotypes are presented in Table I. The isolation 
of prb and pep mutants not in Table  I has been described (26,  69).  The 
procedures used for routine sporulation, dissection, and scoring of nutri- 
tional markers have been described (20).  Scoring of prb mutations using 
Hide Powder Azure overlays (46, 69) andpep mutations using the APE test 
have also been described (26,  66). The mnn/marker was scored with the 
Alcian blue test (16) on unheated cells (4). The alg and glsl markers were 
scored by their effects on the relative mobility of CpY in a 7.5% polyacryl- 
amide-SDS slab gel (29, 36). The relative mobility of CpY was determined 
on an immunoblot of the gel. The kex mutations were scored essentially as 
described (64). The sec18 marker was scored initially by inability to grow 
on yeast extract peptone dextrose (YEPD) (46) at 37°C.  This assignment 
was confirmed by measuring the relative molecular mass of immunoprecipi- 
tated radiolabeled CpY that had been synthesized under nonpermissive con- 
ditions in secl8 and SEC18 cultures. Fluorograms of polyacrylamide-SDS 
gels were used to measure relative molecular mass. Bacteria were trans- 
formed by the CaCI2  method (41). Yeast  were transformed by the LiAc 
method (24) with previously described modifications (66). Piasmid pUC19 
is an E. coli expression vector (67). Plasmid YCp50 is a low copy, centro- 
mere-containing, yeast vector (34). Plasmid pCM5HH is a YCp50 deriva- 
tive containing the PRB1 gene (46). 
Amino-terminal Peptide 
A synthetic pentadecamer peptide corresponding to the 14-amino-terminal 
amino acids of mature PrB (47) plus a  cysteine (sequence =  EFDTQN- 
SAPWGLARC) was purchased from the Yale University Molecular Bio- 
physics and Biochemistry Department,  Protein Chemistry Facility,  New 
Haven, CT. Although analysis of hydrolyzed synthetic peptide verified the 
amino acid composition, reversed-phase  C18-column HPLC analysis showed 
two major and several minor peaks. As determined by protein sequencing 
and fluorescamine tests (37) on HPLC-purified fractions, one of the major 
peaks contained bona fide peptide and the other contained the same peptide, 
but with a blocked amino terminus. Because this peptide was to be used to 
generate antibodies that cross-react with protease B, it seemed prudent to 
purify the genuine peptide from other material that might resemble un- 
related yeast antigens. Approximately 30 mg of genuine peptide and an 
equal amount of blocked peptide were purified from 120 nag of starting ma- 
terial. The purified peptides were divided into aliquots, dried under vacuum 
at room temperature, and stored dry at  -20°C. 
Conjugation of Synthetic Peptide to KLH 
Purified synthetic peptide was conjugated to KLH using the method of Liu 
et al. (40) as modified by Green et al. (17). In this procedure, the bifunc- 
tional cross-linking reagent MBS is first reacted with the primary amine 
groups on a carder molecule (KLH) and then cross-linked to a free sulf- 
hydryl moiety on the hapten (peptide). To maximize productive chemical 
conjugation, the entire procedure, except for dialysis of KLH and dissolu- 
tion of  the peptide, was performed in one day. The entire procedure was per- 
formed a second time on another day, with fresh ingredients, to provide a 
duplicate sample of antigen. 
Synthetic Peptide  A~inity Column 
Purified peptide was conjugated to Affi-gel 10 according to the manufac- 
turer's instructions. Approximately 40 mg of HPLC-purified genuine and 
blocked peptide were dissolved in 450 #1 DMSO and added to 1.1 ml (set- 
tled) freshly DMSO-equilibrated Affi-gel 10 resin. After conjugation and 
washing of the resin, it was poured into a  1.5  x  5.0 cm column, washed 
with 10 mM "Iris, 0.1 mM EDTA, 200 mM NaCI, 0.02%  NAN3, and stored 
in the same buffer. Before affinity purification of antibodies, the column was 
washed with 10 ml of 200 mM glycine, pH 2.0, and 100 ml of 20 mM Tris, 
pH 7.2. 
PRBI ORF Polypeptide 
The plasmid pUCPRB1AH is a pUCI9 derivative in which the PRB10RF 
is under lac transcriptional and translational control.  The ORF protein 
predicted from this fusion would consist of the entire PRB10RF plus a 
9-amino acid amino-terminal extension (sequence =  MITPTLQAK), for 
a predicted molecular mass of 71 kD. The plasmid pUCPRB1AH was trans- 
formed into E. coli strain W3110 (/ac/q) and plated onto Luria Broth (LB) 
(41) plus 100 #g/ml ampicillin. When induced with IPTG, the E. coli strain 
bearing this plasmid produced a 77-kD protein that was recognized by anti- 
bodies to the PrB-peptide.  The IPTG-induced 77-kD  ORF protein was 
purified essentially by the "alternate" method of Drs. T. J. Koerner (Duke 
University, Durham, NC) and A. M. Myers (Iowa State University, Ames, 
IA) for purifying trpE fusion proteins (personal communication), as fol- 
lows. One fresh colony was inoculated into 10 ml M9 medium (41) sup- 
plemented with 0.5 % casamino acids and 100 #g/ml ampicillin. The culture 
was grown at 37"C with vigorous agitation until it reached mid-log phase. 
The entire culture then was added to 100 rod of the same medium in a 2 liter 
flask for an additional 1-2 h of growth, at which time IPTG was added to 
a final concentration of  5 raM. After 4 h, the culture was placed at 4°C with- 
out shaking. The next day the cells were pelleted, washed in 10 mM Tris, 
pH 7.5, and resuspended in 20 ml of 50 mM Tris,  pH 7.5, 5 mM EDTA, 
3 mg/ml lysozyme. After a 2-h incubation on ice, 1.4 ml of 5 M NaCI was 
added. The solution was mixed, 1.5 ml of 10% NP-40 was added, and the 
solution was mixed again. After incubation on ice for 30 rain, the resulting 
solution was sonicaaxt in l-min bursts until it was no longer viscous. The 
insoluble fraction, which was greatly enriched for the fusion protein, was 
collected by centrifugation at 12,000 g at 4°C for 10 min. This pellet was 
washed once with 20 ml of 1 M NaCI, 10 mM Tris, pH 7.5, and once with 
20 ml of 10 mM Tris,  pH 7.5. The pellet was resuspended in 1 ml of 10 
mM Tris, pH 7.5, with a loose-fitting hand-held Dounce homogenizer, 7 ml 
from Fisher Scientific, Philadelphia, PA. 
Immunization of Rabbits 
One rabbit was immunized with subtilisin and three rabbits were immunized 
with proteinase K, as these two proteases share significant protein sequence 
identity with PrB (35 and 43 %, respectively; 47) and are also commercially 
available.  Antibodies were raised that recognized subtilisin at a dilution of 
1:5,000; we were unable to raise antibodies to proteinase K. (We suspected 
that the major extracellular protease ofNeurospora crassa [1] also might be 
similar to protease B [47], so immunobiots of yeast extracts were probed 
with antibodies to the Neurospora protease. These antibodies also failed to 
cross-react with PrB.) 
Three rabbits (R31, R32, and R35) were immunized with the first pep- 
tide-KLH  conjugate,  and  three rabbits (R34,  R36,  and  R37)  were im- 
munized with the second. All six rabbits were treated similarly. All injec- 
tions contained 0.2  nag of conjugate.  The  initial subcutaneous injection 
contained antigen in 0.7 ml of 50% Freund's complete adjuvant and all sub- 
sequent intramuscular injections contained antigen in 0.25 m150% Freund's 
incomplete. The intramuscular injections were given 2 and 4 wk after the 
initial subcutaneous one, and then every 4-6 wk thereafter. The rabbits were 
bled once a week during the 3-wk period after the second and all subsequent 
intramuscular injections. The immune serum from R31, R32, and R35 con- 
tained antibodies that recognized PrB on Western blots (7) at dilutions of 
from 1:100 to 1:250, from R37 at 1:32; an insignificant amount of  antibodies 
that recognized PrB were obtained from R34 and R36. For most peptide an- 
tibody experiments, serum from R35 was used. 
Three additional rabbits (R48,  R50,  and R52) were immunized under 
contract with Bethyl Labs (Montgomery, TX). For these three rabbits, all 
injections were subcutaneous with Freund's complete adjuvant. For rabbits 
R48 and R50 each injection contained 300 #g of protein (estimated from 
Coomassie Blue-stained polyacryfamide gels) from the insoluble fraction 
of  the PrB ORF protein preparation. After seven injections, neither R48 nor 
R50 produced a reasonable titer of antibodies that recognized PrB. For rab- 
bit R52 each injection contained 75-100 #g of polyacrylamide gel-purified 
protein from the insoluble fraction of the PrB ORF protein preparation. For 
the first three of tbese injections the protein was in a pulverized Z5% poly- 
acrylarnide gel slice equilibrated with PBS; for all subsequent injections the 
protein was electroeluted (23; Elutrap; Schleicher & Schuell, Inc.) from the 
gel. After the fifth injection, R52 produced an excellent titer of antibodies 
that recognize protease B. 
Purification of  Anffpeptide Antibodies 
All steps of this purification were carried out at 4°C. Rabbit serum that 
reacted with PrB from yeast extracts was pooled and (NI-h)2SO4 was added 
to a final 50% saturation. The 50% (NI-h)2SO4 pellet was resuspended in, 
and dialyzed extensively against, 20 mM 'Iris, pH 7.2.  After dialysis, in- 
soluble material was removed by centrifugation at 12,000 g for 20 rain. Ali- 
quots of dialysate were loaded on the Affi-gel 10--peptide column, and the 
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at which time antipeptide antibody was eluted with 0.2 M glycine, pH 2.3. 
Elution continued until the A2so was <0.02. Elnted fractions were neutral- 
ized with  1 M  "Iris base, and the A2ao monitored. Peak fractions were 
precipitated in 2  M  (NH4)2SO4. The pellet was resuspended in and dia- 
lyzed against PBS. The breakthrough fractions were pooled and reapplied 
to the column until there was no longer a  significant peak eluted.  This 
column yielded 1--4 mg of antibody per elution. 
Antibodies to Protease B 
Because purified protease B was difficult to obtain, synthesis of a PrB pep- 
tide was commissioned and the peptide was used to generate and affinity 
purify antibodies. The affinity purification was successful at removing con- 
taminating antibodies to many other proteins, but resulted in enrichment for 
antibodies to a 55-kD protein that is not encoded by the PRB1 locus even 
more than for antibodies to PrB (45; data not shown). The affinity-purified 
antibodies worked well on immunoblots, but were not very effective in im- 
munoprecipitations. Interestingly, these antibodies showed a weak reaction 
against the Neurospora extraeellular protease, and a strong reaction against 
proteinase K (data not shown). The reaction against proteinase K is not sur- 
prising insofar as eight residues of the peptide are identical to the amino 
terminus of the protease; the sequence of the Neurospora protease is not 
known. 
The PRB1 ORF was placed under/ac control in the plasmid pUCPRBI AH. 
The plasmid was constructed so that the lac promoter, operator, and ribo- 
some-binding site directed the synthesis of a 644-amino acid protein that 
consisted of the laeZ initiating Met,  followed by 8-amino acid residues 
(ITPTLQAK), and then the entire 635 residue PRB1 ORE  Expression of 
a 77-kD  protein was induced with the gratuitous inducer IPTG. The PrB 
peptide antibodies were used to verify that this 77-kD protein was encoded 
by the 644-codon chimeric ORF in the plasmid, and that the induced pro- 
tein partitioned into an insoluble protein fraction (45; data not shown). Both 
the crude insoluble protein fraction and polyacrylamide gel-purified ORF 
protein were injected into rabbits. The crude insoluble fraction was not an 
effective antigen, but the purified protein was. Antiserum to the gel-purified 
protein reacted strongly with PrB on immunoblots at dilutions of at least 
1:500. This antiserum was also very effective in immunoprecipitation ex- 
periments. Unfortunately, the gel-purified 77-kD ORF protein could not be 
conjugated to Affi-gel 10 or Affi-gel 15 under any of several conditions 
recommended by the manufacturer. Therefore, for most experiments, the 
affinity-purified peptide antibody was used in immunoblots, and the 77-kD 
ORF protein antibody was used in immunoprecipitations. 
lmmunoblots 
Yeast extracts were prepared from stationary phase, liquid YEPD-grown 
cultures. Approximately 3  x  108 cells (A600 =  30) were harvested per cul- 
ture in 13  x  100 mm glass tubes and washed once with 2 ml of phosphate 
extract buffer (20 mM sodium phosphate, pH 7.4, 0.15 M NaCI). To the cell 
pellets were added 0.4 g glass beads (0.44-0.46 mm diana) and 50 #1  1% 
SDS. The protein was extracted by 90 s of vortexing followed by 3 min of 
boiling. The extracts were briefly chilled in an ice bath and 450 #1 of 1% 
Triton X-100 was added. The cell debris was removed by centrifugation at 
27,000 g  for 20 rain.  The proteins were separated by subjecting them to 
PAGE (36). Typically,  7.5% acrylamide gels were used for assessing CpY, 
and 10%  gels were used for PrA and PrB. 
Immunoblots were made as described (7). The proteins were transferred 
to nitrocellulose in 24 mM Tris, 192 mM glycine, 20% methanol. The ex- 
tent of protein transfer to nitrocellulose was assessed by staining with Pon- 
ceau S and destaining with water. This stain reversibly binds to proteins and 
is removed with PBS. Immune complexes were visualized using a Vectastain 
kit according to the manufacturers instructions, except that the secondary 
antibody (biotinylated goat anti-rabbit) was diluted by an additional factor 
of 10. 
In Vivo Labeling, Immunoprecipitations, 
and Fluorography 
Growth of cultures and immunoprecipitations were performed essentially 
as described (31) with slight modifications. Typically,  BSA was not added 
to the labeling medium, but was added with the antibodies. After 10-20 min 
of labeling, an optional chase was initiated by adding 1 M  MgSO4  to a 
final concentration of 50 mM for 40-60 min. The cultures were stopped by 
mixing them with one-fourth volume of 25%  TCA and incubating on ice 
for 20 min or longer. If tunicarnycin was used, it was added from a 1 mg/ml 
DMSO stock to a final concentration of 20 #g/ml 15 min before adding la- 
bel. The secT, 11, 14, 18, 53, and 59 mutants were shifted to 37"C  10 rain 
before adding label, and kept at that temperature during labeling. The sec61 
and sec62 mutants were shifted to 37"C 10-60 min before labeling, and kept 
at that temperature during labeling. Usually a 2-t~l sample of this extract 
was subjected to liquid scintillation counting to measure incorporation of 
label:  a  typical extract contained  1  x  107-5  x  l0  s  cpm.  The  protein 
A-Sepharose had been prepared by swelling 0.4 g of the dry resin in 11.2 
ml of 10 mM Tris, pH 7.5,  1 mg/ml BSA, 0.02%  NaN3 at 4°C for 4 h or 
longer, then removing the supernatant, and adding an equal volume of the 
same buffer. The final pellet was resuspended in 50 #1 of SDS sample buffer, 
and a 4  #1 aliquot of the supernatam was counted. 
For pulse-chase experiments, essentially the same procedure was used. 
When labeling with [3SS]methionine  (Trans3SS, an 3sS-iabeled  bacteria hy- 
drolysate), the cells were not subjected to a sulfur starvation, and, instead 
of MgSO4,  were chased with unlabeled methionine plus cysteine, at  a 
4,000-fold excess. Labeled methionine was 4.4 #M, or less, and the unla- 
beled amino acids were 17 mM each. 
Occasionally it was desirable to assess two different proteins from the 
same labeled culture. To do this, the cell extracts were saved after the first 
immunoprecipitation, and any residual antibody was adsorbed with an addi- 
tional 40/d of  protein A-Sepharose. The first and second irnmunoprecipita- 
tions then were performed on the extract with antibodies to the second pro- 
tein of interest. 
Labeled,  immunoprecipitated proteins  were  analyzed  on  polyacryl- 
amide-SDS gels, 1.5 mm thick (36). For each gel, the samples were nor- 
realized so as to load comparable amounts of radioactivity per lane. The 
radioactive proteins  were  visualized by  fluorography  using  either  EN- 
HANCE or AUTOFLUOR according to the manufacturers' instructions. 
Addition to the AUTOFLUOR of glycerin to a final concentration of 5 % 
considerably improved the handling and drying qualities of the gels. Either 
Kodak XAR or XRP film was used. As 3ss decay does not produce enough 
energy to expose both sides of two-sided film, the emulsion on the unex- 
posed side of (dry) developed films was removed with household bleach. 
This reduced the background by 50%  without affecting the signal. 
Results 
Protease B in Crosses of a pelM Mutant with alg5 and 
alg6 Mutants 
To determine the number of chains and the extent of glycosy- 
lation in mature PrB and its zymogen that accumulates in 
pep4 mutants, several known glycosylation mutations (alg5, 
alg6, glsl, and mnnl ) were tested for their effects  on PrB in 
both PEP4 and pep4 genetic backgrounds. Mutations in the 
ALG5 or ALG6 genes result in failure to add three glucose 
residues to the dolichol-linked glycolipid donor, which in 
turn reduces the efficiency of transfer of full-length chains to 
asparagine residues in polypeptides (22,  38, 54) including 
CpY (29). An alg5 and an alg6 mutant were each crossed to 
a pep4 mutant (BJ2589  x  K13496 and BJ2590  ×  BJ3493, 
respectively). Protein transfer blots of extracts from the par- 
ent  strains  and  several  tetrads  from  these  crosses  were 
probed with antibodies to the PrB peptide.  The alg6 PEP4 
strains accumulated normal mature PrB, but the alg6 pep4 
strains accumulated two protease B species (Fig. 1). One spe- 
cies comigrated with the pep4 zymogen form, and the other 
was smaller by 2.8 kD, or the size of one Asn-linked carbohy- 
drate chain. These results indicate that the 40-kD zymogen 
form contains one Asn-linked carbohydrate side chain but 
that the mature enzyme contains no Asn-linked chains. The 
alg5 mutation had no effect on PrB,  regardless of the PEP4 
genotype (data not shown); this finding is in agreement with 
the relatively weak effect of the alg5 mutation on CpY (29) 
and secreted invertase (22). 
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of full-length  carbohydrate  chains  to the  asparagine  residues  of 
polypeptides is less efficient in alg6 mutants (54). The size of ma- 
ture PrB was the same in ALG6 and alg6 strains. In a pep4 back- 
ground the alg6 mutant contained an additional PrB species that 
was smaller by 2.8 kD, the approximate size of one Asn-linked car- 
bohydrate side chain. Since glycosylation occurs in the ER bofore 
PEP4-mediated  processing (57), PrB had at least one side chain that 
was present on the precursor that accumulated in pep4 strains, but 
was not present  on the mature  protease.  From left to right,  the 
strains used  in this immunoblot  were:  BJ2590, BJ3493, and one 
tetratype tetrad  from this cross,  BJ3629-BJ3632. 
PrB in glsl and pep4 glsl Mutants 
After transfer of a completed Glc3Man9GlcNAc2  chain from 
the dolichol carrier to an asparagine residue, the three glu- 
cose residues are removed (38) by the GLS1 gene product 
(12).  A glsl mutant was crossed to a pep4 mutant (BJ3622 
×  BJ3496).  Protein  extracts  were  made  from the  parent 
strains and several tetrads from this cross. Immunoblots of 
these extracts showed that the glsl mutation had no effect on 
mature PrB.  However, the PrB species that accumulated in 
the glsl pep4 strain was larger than that in the GLS1 pep4 
strain by 500-700  D,  or the  size of three  to  four glucose 
residues  (Fig.  2).  Therefore,  the results with the alg6 and 
glsl mutants were consistent with the PrB zymogen having 
one Asn-linked side chain, and the mature protease having 
none. 
PrB in mnnl and pep4 mnnl Mutants 
The mnnl mutant is reported to be defective in the addition 
of mannose residues to glycoproteins via od-3 linkages and, 
therefore, defective in both Asn-linked and hydroxyl-linked 
glycosylation (8, 49, 52).  An mnnl mutant was mated with 
apep4 mutant (BJ3638  x  BJ3493). Immunoblots of extracts 
from the parent strains and several tetrads from this cross 
were probed with antibodies to the PrB peptide.  The nmM 
mutation had no effect on PrB regardless of the PEP4 geno- 
type (data not shown). 
Determination of  PrB Structure in sec61 and 
sec62 Mutants 
Existence of the 635  residue ORF led us to believe that a 
precursor much larger than 42 kD should exist. The expected 
size of this precursor was >69 kD (47). When placed under 
restrictive conditions, see61 and see62 mutants accumulate 
unglycosylated precursor forms of CpY, mating factor a, and 
Figure  2. PrB phenotype of glsl and gls! pep4 mutants. Asn-linked 
glycosylation involves transfer to the protein ofa preassembled side 
chain containing three glucose residues. After transfer, but before 
passage from the ER, the three glucose residues are removed by the 
GLSI gene product (12). The size of mature PrB was the same in 
GLS1 and glsl strains. In the glsl pep4 strain, PrB was 500-700 D 
larger than in the GLM pep4 strain. Therefore, mature PrB did not 
contain any Ash-linked carbohydrate, but the zymogen form con- 
tained one such side chain.  From left to right,  the strains used in 
this  immunoblot  were:  the  diploid  BJ3496  x  BJ3622, BJ3622, 
BJ3496, and one tetratype tetrad from this cross, BJ3655b-BJ3658. 
In this cross  a secl8 mutation  was also segregating,  so care was 
taken to culture all of these strains at 23-25°C. 
secreted invertase that fail to enter the ER (10).  A larger PrB 
precursor would also be expected to accumulate in sec61 and 
sec62 mutants.  Under nonpermissive conditions, these two 
mutants accumulated a 74-78-kD PrB species, 76-kD in sub- 
sequent discussion (see Figs. 8 and 9; these figures are fully 
discussed  later).  The observed size was close to that pre- 
dicted from the PRB1 ORE Tunicamycin had no effect on the 
size of the 76-kD form of PrB, which is in keeping with this 
being an unglycosylated, presecretory, or pre-ER, PrB spe- 
cies (45;  data not shown). 
Determination of  PrB Structure in Mutants Defective 
in ER Functions 
The secl8 mutation belongs to a group of conditional muta- 
tions that prevent transfer of secretory proteins from the ER 
to the Golgi apparatus under nonpermissive conditions. When 
placed at a  nonpermissive temperature,  secl8 mutants ac- 
cumulate an  under-glycosylated ER  form of CpY and  se- 
creted invertase (13, 51). In the ER, the GLS1 gene product 
removes three glucose residues from each Ash-linked carbo- 
hydrate side chain. In glsl mutants, the glucose residues are 
not removed, but this does not interfere with secretion and 
processing of the glycoprotein (12).  These two ER-function 
mutations were tested for their effects on PrB in in vivo-la- 
beled cells. (Under the labeling conditions used for this ex- 
periment,  i.e.,  10 min of labeling at 37°C  followed by no 
chase, PEP4 strains behaved like leaky pep4 phenocopies. 
In  other  words,  the  PEP4 strains  accumulated  significant 
amounts of proprotease B.) Consistent with the immunoblot 
experiments  described  above,  proprotease  B  was  slightly 
larger in the glsl strains than in the equivalent GLS1 strains 
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in Wickerham minimal proline, preincubated for 10 min at 37°C, 
and labeled for 10 min at 37°C  with [35S]sulfate without any sub- 
sequent chase. Under these conditions, PEP4  strains were slightly 
leaky pep4 phenocopies;  that  is,  they accumulated  a  substantial 
amount of proPrB. Strains used and relevant mutations were: lane 
1, BJ3658 (glsl); lane 2, BJ1984 (pep4); lane 3, BJ1983 (+); lane 
4, BJ3655b (secl8); lane 5, BJ3656 (sec18 glsl). 
(Fig.  3).  Somewhat surprising was the finding that PrB in a 
sec18 mutant was nearly  the same size as in a pep4 mutant 
(39  and 40  kD,  respectively).  This  suggested that a  major 
proteolytic processing event occurred before the protein left 
the ER.  Except for the signal peptidase cleavage, we know 
of no other example of proteolytic processing  in the ER of 
yeast.  The relative molecular mass of PrB was smallest in 
the sec18 mutant and was incrementally  larger in the pep4, 
sec18 glsl, and (by inference) pep4 glsl mutants (Fig. 3). Be- 
cause a  change in the GLS1 genotype results in a  change in 
the size of PrB by three hexose units in these pairs, it can be 
inferred from Fig. 3 that the pep4 PrB species could be only 
one or two hexose residues larger than the sec18 PrB species. 
To distinguish whether the differences in PrB relative mo- 
lecular  mass observed  in pep4,  secl8,  and pep4 glsl  mu- 
tants were due to elaboration of Asn-linked glycosylation, or 
some  other  event  such  as  elaboration  of  hydroxyl-linked 
glycosylation, these mutants were labeled in the presence of 
tunicamycin. The PrB species that accumulated in tunicamy- 
tin-treated pep4, sec18, and pep4 glsl mutants were indistin- 
guishable from one another (Fig. 4). Therefore, the relative 
molecular mass difference between the PrB species in a pep4 
Figure 4.  The effect of tunicamycin on PrB  in  wild-type, pep4, 
sec18, and pep4 glsl mutants. Cultures were grown in Wickerham 
minimal proline medium and labeled for 10-15 min with [35S]sul- 
fate. All strains except the secl8 mutant (BJ3655b)  were pregrown 
and  labeled at 22°C.  Strain BJ3655b  was grown at 22°C,  prein- 
cubated for 15 min at 37°C, and labeled at 37°C. Cell extracts were 
subjected  to  immunoprecipitation  with  antibodies  to  the  77-kD 
ORF protein. Strains used and relevant mutations were: lanes I and 
2, BJ1983  (+); lanes 3, 6,  7, and 10, BJ1984  (pep4); lanes 4 and 
8, BJ3748 (sec18); lanes 5 and 9, BJ3656 (pep4 glsl ). The cultures 
represented by lanes 2 and  7-10 were treated with tunicamycin. 
and a secl8 mutant must be due entirely to a difference in the 
Ash-linked side chains. Insofar as the Asn-linked side chains 
on invertase that accumulated in the secl8 mutant were of the 
composition ManaGIcNAc2 (12),  the  side chain  on propro- 
tease B in the pep4 mutant was probably of the composition 
Mant0GlcNAc2.  The data in Fig. 4  also confirm that mature 
PrB  does  not  contain  any  tunicamycin-sensitive  carbohy- 
drate. 
Strains carrying mutations in the SECll, SEC53, or SEC59 
genes,  whose gene products are believed to be required  for 
functions  between  those  of  the  SEC61/SEC62  pair  and 
SEC18, were examined  for their  effects on PrB processing. 
The SECll gene is believed to encode a subunit of yeast sig- 
nal peptidase (6). After in vivo labeling under nonpermissive 
conditions  and immunoprecipitation of protein extracts, the 
PrB species that accumulated in a secI1 mutant was the same 
size as that in a secl8 mutant (Fig.  5).  Therefore, the SECll 
gene product is not required  for processing of PrB from 76 
to 39 kD. 
Mutants carrying alleles in either SEC53 or SEC59 genes 
are known to accumulate early ER forms of CpY and secreted 
invertase  under  nonpermissive  conditions  (15).  Both  the 
sec53 and sec59 mutants gave identical results with respect 
to PrB (Fig. 6): two proteins accumulate that cross-react with 
antibodies  to the 77-kD PRB1-ORF  protein.  One protein is 
the same size as mature PrB (31 kD), and the other is about 
the  same  size  as  unglycosylated  proPrB  (37  kD).  These 
results are preliminary:  it is not known from what part(s) of 
the PRB10RF these  two  proteins  come,  nor  is  it  known 
whether  either of them is glycosylated. 
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species accumulating in a sec- 
59 mutant.  The see59  strain 
was grown at 23°C in Wicker- 
ham minimal proline medium, 
preincubated  for  10  min  at 
37°C, and labeled  for 10 min 
at 37°C with [35S]sulfate with- 
out any subsequent chase. The 
SEC59  strain  was  grown  at 
23°C  in  Wickerham  mini- 
mal  proline  medium and  la- 
beled for 10 min at 23°C with 
[35S]sulfate followed by a 40- 
min chase.  Cell extracts  were 
subjected  to  immunoprecipi- 
tation  with  antibodies  to the 
77-kD ORF protein. The sec59 
mutant accumulated two forms 
of PrB,  one  that  comigrated 
with mature PrB, and another 
that  was  •37-38  kD,  or  in 
the size range  of the PrB zy- 
mogen without its Asn-linked 
side chain. The sec53 (BJ2388) 
and see59 mutants gave identi- 
cal results (not shown).  Since 
antibodies  to the 77-kD ORF 
protein were used, we do not 
know from which part of the 
open reading  frame either of 
these  proteins  were  derived. 
Strains used and relevant mu- 
tations  were: BJ2390 (see59) 
and BJ1983 (SEC59). 
Figure 5. Accumulation ofa 39-kD species of PrB antigen in a sec11 
mutant.  Cultures were grown at 23°C in Wickerham minimal  pro- 
line medium, preincubated  for 10 min at 37°C, and labeled  for 10 
min at 37°C with [35S]sulfate without any subsequent  chase.  Pro- 
tein extracts were subjected to immunoprecipitation  with antibodies 
to the 77-kD ORF protein.  Both the see11 and secl8 mutants  accu- 
mulated a 39-kD form of PrB-related  protein.  Strains used and rele- 
vant mutations  were:  BJ3748 (secl8) and BJ4378 (see11). 
Determination of PrB Structure in Mutants Defective 
in Golgi Complex Functions 
The sec7 and secl4 mutations belong to a class of mutations 
that  are  conditionally  defective  in  translocation  from  the 
Golgi complex. When placed at a nonpermissive temperature, 
the  sec7 mutant  is  known to accumulate  a  slightly  under- 
glycosylated form of proCpY and secreted invertase.  Under 
these same conditions the secl4 mutant accumulates proCpY 
that is identical  in size to that found in pep4 mutants  (57). 
We confirmed that the sec7 (BJ2159) and secl4 (B  J2160) mu- 
tations had a similar effect on PrB processing as they did on 
CpY. The sec14 andpep4 mutants accumulate identical-sized 
PrB species, and the sec7mutant accumulated a PrB species 
of a  size intermediate to that of the sec18 and sec14 mutants 
(data not shown). 
Short Lifetime of the 76-kD Precursor 
While the 40-kD precursor was previously identified in ki- 
netic experiments  (44),  the 76-kD precursor had not been 
identified, even in the absence of a chase. This suggested that 
the 76-kD precursor is rapidly processed to the 40-kD inter- 
mediate, and, that after a 20-min pulse (44), the fraction of 
labeled PrB represented by the 76-kD species must be almost 
zero. This hypothesis was borne out by a pulse-labeling ex- 
periment  in  which  pS]sulfate  was  added  to  one  culture, 
and samples were removed at several time points  (Fig.  7). 
There was no chase;  at the end of the labeling interval the 
samples were stopped with cold TCA. After 4 min of  labeling 
at  18-21°C  (Fig.  7,  lane 4),  the 76-kD species  already ac- 
counted for less than half of the total labeled  PrB.  After 6 
min of labeling (Fig.  7, lane 5), the fraction of labeled PrB 
represented by the 76-kD species was nearly zero. The 76-kD 
species  was  processed  to  the  40-kD  intermediate  in  one 
quick step,  with no trace of the other half of the precursor 
(Fig. 7). (The antiserum used in this experiment does recog- 
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length of pulse labeling.  Cultures  were grown in 
Wickerham minimal  proline medium, starved for 
sulfur, and labeled  with [35S]sulfate. Cell extracts 
were subjected  to immunoprecipitation  with anti- 
bodies to the 77-kD ORF protein. Lanes 2-9 rep- 
resent a pep4 mutant  (BJ1984) labeled  for 1:12, 
2:07,  4:05,  6:01,  7:05,  10:05,  14:22,  and 20:10 
minis, respectively, with no chase. Lane 1, 13.13947 
(sec61); lane 10, BJ3748 (sec18); lane//,  BJ1983 
(+);  lane  12,  BJ1984  (pep4); lane  13,  BJ3044 
(prbl-A1.6). For lanes 11-13, the cultures  were la- 
beled for 15 min, and chased for 40 min. All sam- 
pies were adjusted to a comparable number of cpm 
before  loading. 
nize epitopes in the first 280 amino acids of the PrB ORF 
[data not shown].) 
Processing of PrB in Pulse-Chase Experiments 
Labeling with sulfate for <4 min resulted in an unsatisfactory 
level of label incorporation, yet after labeling for 4 min, the 
early  form(s)  of labeled  PrB were difficult to see because 
they represented  a  very  small  fraction of the total labeled 
PrB.  Accordingly,  [35S]methionine  (Tran35S)  labeling  was 
used. A preliminary experiment with a 30--40-s pulse of la- 
bel provided excellent resolution of early species  (Fig.  8). 
Figure 8. PrB in a pulse-chase experiment.  This figure shows the 
results  of two  [35S]methionine  pulse-chase  labelings  of  strain 
BJ1983  (MATct trpl).  Cells were grown in Wickerham minimal 
proline medium supplemented  with adenine,  histidine,  leucine,  ly- 
sine, tryptophan, and uracil.  Enough cells  were harvested  to give 
1.50D per time-point and resuspended  at 4.50D per ml in fresh 
medium plus 0.55 mCi [35S]methionine per time-point at 25°C. In 
both cultures, the radioactive  label was chased by adding unlabeled 
methionine  and cysteine to a  final concentration of 3.6 raM.  For 
both cultures, the chase was initiated 30--40 s after adding label and 
samples were taken after initiating the chase at the times indicated. 
Control strains  +  (BJ1983 with a 40-rain chase), pep4 (BJ1984), 
sec18 (BJ3748), and sec61 (BJ3947) were labeled  with [35S]sulfate. 
Molecular mass standards are shown on the right side of the figure. 
All samples  were adjusted to a comparable number of clam before 
loading. 
The Journal of Cell Biology, Volume 108, 1989  316 Figure 9.  PrB and CpY in a pulse-chase experiment.  The results  of three [~SS]methionine pulse-chase labelings  of strain BJ3044 (prbl- 
AL6) transformed  with either the control vector YCp50 (C) or the PRBl-containing  vector pCM5HH (A and B) are shown.  Cells were 
grown in Wickerham minimal proline medium supplemented  with adenine,  histidine,  leucine,  lysine,  tryptophan, alanine,  and glycine. 
(Extra nutritional  supplements  allowed the ceils  to grow and label better without interfering  with PRB1 expression.)  Enough cells  were 
harvested to give 20D per time-point,  and resuspended  at 80D per ml in fresh medium. The three cultures  were grown at 25°C with 
(A) or without (B and C) tunicamycin for 15 min before adding [35S]methionine (2.77 mCi forA and C, 4.42 mCi for B). In each culture, 
the radioactive  label  was chased by adding an equal  volume of medium containing 33 mM each of unlabeled  methionine and cysteine. 
For A (Prb  ÷,  +tunicamycin), the chase was initiated  1:58 min/s after adding label.  The time-points  were taken at 1:30, 3:30, 6:15,  12, 
and 24 min/s after adding label (A, lanes 1-5, respectively).  For B (Prb  ÷,  -tunicamycin), the chase was initiated at 1:20 min/s after add- 
ing label.  Samples were taken at 0:40, 2:20, 3:30, 6:00,  12, 24, 48, and 92 min/s after adding label  (B, lanes  1-8, respectively).  For C 
(Prb-,  -tunicamycin), the chase was initiated  at 1:30 min/s,  and samples  were taken at 0:40, 2:30, 3:30, 6:00, and 12 min/s after adding 
label (C, lanes 1-5, respectively).  For D-F, the cell extracts used for A-C were subjected  to a second immunoprecipitation  with anti-CpY 
(see Materials  and Methods).  Control strains  BJ3748 (sec18), BJ1984 (pep4),  BJ3947  (sec61), and BJ3944 (sec62) were labeled  with 
[aSS]sulfate. All samples  were adjusted  to a comparable number of cpm before loading.  Molecular mass standards  are indicated  on the 
left side of the figure.  On the right side,  major forms of PrB or CpY are indicated  by their molecular mass or by the nomenclature of 
Stevens et al.  (57). 
That the initial species detected with no chase matures into 
a  slightly larger species by 1 min of chase is evident.  How- 
ever, a 30--40-s pulse still provided an unsatisfactory level of 
label incorporation and also revealed extraneous bands >76 
kD that may or may not be related to PrB.  In a  subsequent 
set  of pulse-chase  experiments,  these  problems  were  ad- 
dressed by: (a) taking the first time point at 40 s, but continu- 
ing the labeling pulse up to 80 s  (Fig.  9);  and (b) labeling 
a prbl-AL6 strain that was transformed with the control vec- 
tor YCp50 (Fig. 9 C), and the same strain transformed with 
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Protease B was first synthesized as a 76-kD unglycosylated 
precursor that comigrated with the sec61/sec62 species (Fig. 
9 B). This precursor chased into a short-lived, larger inter- 
mediate of ~78 kD (Fig. 9 B, lane 2).  The increase in size 
appeared to be due to Asn-linked glycosylation, as the in- 
crease was not seen in tunieamycin-treated ceils (Fig. 9 B). 
Within  3:30 min of adding label (Fig.  9 B, lane 3),  nearly 
all of the 78-kD intermediate was processed, in one step, to 
a 39-kD species that comigrated with the form found in secl8 
mutants.  By 24 min (Fig.  9 B,  lane 6),  all of the PrB had 
chased to the 40-kD intermediate that accumulates in pep4 
mutants.  (In the  experiment with  a  30-s pulse,  a  discrete 
form, intermediate in size between the sec18  andpep4 forms, 
of PrB could be identified with shorter exposure times than 
that shown.) At 24 min, a slightly smaller, 37-38-kD inter- 
mediate appeared, which in turn was chased to the 31-kD ma- 
ture PrB. The size of the 37-38-kD intermediate is reduced 
in the presence of tunicamycin, indicating that it is glycos- 
ylated (Fig. 9 A). The labeled cell extracts that gave rise to 
Fig. 9, A-C were subsequently subjected to another immuno- 
precipitation with antibodies to CpY (Fig. 9, D-F). At 25°C, 
processing from the ER form to thepep4 zymogen form and 
then to the mature form was similar for PrB and CpY. 
Amino Terminus of the 40-kD Species 
In an earlier report, we predicted that protease A-mediated 
processing of the 40-kD intermediate to 31-kD mature PrB 
occurred via a carboxy-terminal cleavage (47). Proof of this 
hypothesis would come from an unequivocal determination 
that the two species had different carboxy termini but identi- 
cal amino termini. Demonstration of the former would have 
been technically much more difficult, so we pursued the lat- 
ter.  Unfortunately,  so  far  we  have been unable  to  purify 
enough of the 40-kD precursor for sequencing, but the pep- 
tide antibody allowed a demonstration that both the 40-kD 
precursor and mature protease B  probably share the same 
amino terminus. A PEP4  and apep4 strain were labeled with 
[35S]sulfate, chased, and protein was extracted. One-half of 
each extract was subjected to two sequential immunoprecipi- 
tations with antibodies to the PrB peptide, and the other half 
Figure 10. (A) Shared amino terminus of the 31-kD mature and 40- 
kD zymogen forms of PrB. Radiolabeled cell extracts of BJ1983 
(PEP4, lanes I and 2) and BJ1984 (pep4, lanes 3 and 4) were pre- 
pared as before. PrB was immunoprecipitated with either affinity- 
purified antibodies to the peptide-KLH conjugate (lanes 1 and 3), 
or antiserum to the 77-kD ORF protein (lanes 2 and 4). The affinity- 
purified antibodies identified an additional 16-kD protein common 
to both strains. See text for further details. (B) Three hypothetical 
interpretations for the results in A. The figure is discussed fully in 
the text. Definition of symbols used: AA, amino acid followed by 
position number with respect to the amino terminus of mature PrB; 
N and C, amino and carboxyl termini of the polypeptide,  respec- 
tively; t or ~, proposed site of cleavage(s) necessary to generate the 
16-kD degradation product. The horizontal lines between N and C, 
represent the polypeptide drawn to a scale based on the apparent 
molecular mass of the glycoprotein. The small open box designates 
the target site for the affinity-purified antibodies. The upside-down 
Y represents the hypothetical location of the Asn-linked carbohy- 
drate chain of the PrB zymogen. 
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ture. All strains were grown to stationary phase in YEPD. Protein 
was extracted and fractionated on a polyacrylamide gel and trans- 
ferred  to nitrocellulose.  The blots  were  incubated  with  atiinity- 
purified antibodies to the amino-terminal  PrB peptide. The bands 
indicated on this immunoblot are A, 40-kD pep4 zymogen form of 
PrB; B, 37-kDprb1-628  inactive form; C, 31-kD PEP4PRB1  mature 
form.  The strains used in this  immunoblot  were:  BJ3496 (MATa 
PRB1 pep4::HIS3 ), B  J52 (MATer  prbl-628  PEP4), one parental di- 
type tetrad and one tetratype tetrad from this cross. 
was subjected to two sequential  immunoprecipitations with 
antiserum to the 77-kD ORF protein. In both PEP4 andpep4 
strains, the antibodies to the amino terminal peptide recog- 
nized the expected 31- or 40-kD PrB species (Fig.  10 A). In 
addition, there was one major PrB degradation product of 16 
kD common to both PEP4 and pep4 strains that was recog- 
nized by the  purified peptide antibodies,  but not the ORF 
protein  antiserum  (Fig.  10 A).  As  a  control,  labeled,  ex- 
tracted proteins from thepep4 strain were subjected to a first 
immunoprecipitation with the ORF protein antiserum;  the 
immunoprecipitate was then subjected to a second precipita- 
tion, where one-half received ORF antiserum and the other 
half received peptide antibodies. Again, the 16-kD fragment 
was precipitated by the peptide antibody but not by the ORF 
antibody  (data not  shown),  demonstrating  that this  16-kD 
species is an in vitro degradation product rather than an un- 
related  protein  recognized  only  by  the  antipeptide  anti- 
bodies. 
Fig.  10 B  represents three hypothetical interpretations of 
the results shown in Fig.  10 A. In the first case, both PrB and 
proPrB have the same amino terminus,  and both have one 
common site that is sensitive to artifactual cleavage. In the 
second case, both PrB and proPrB have the same carboxy 
terminus, and both have the same common sensitive site, but 
in addition, proPrB is cleaved a second time at the site corre- 
sponding to the mature PrB amino terminus. Note, however, 
that in Fig.  10 A there are no obvious intermediates between 
the 40- and 16-kD species, so the two cleavages would have 
to be nearly simultaneous.  In the third case, both PrB and 
proPrB have the same carboxy terminus, but they would have 
to have two different sensitive sites that coincidently give rise 
to stable degradation products that are identical in size. That 
the 40-kD species could undergo either two simultaneous ar- 
tifactual cleavages, or a single cleavage, albeit different from 
that of mature PrB, to yield a stable degradation product the 
same  size  as  the  mature  PrB  degradation  product  seems 
highly unlikely.  Therefore, the 40- and 31-kD PrB species 
probably have the same amino terminus, and protease A-me- 
diated processing occurred at the carboxy terminus of PrB. 
Processing of  PrB in kexl, kex2, and 
kexl kex2 Mutants 
The  results  described  above demonstrated  that  preproPrB 
was being processed in  the  ER  by one or more proteases 
other than protease A. Two known processing proteases for 
which mutants are available are the KEX1 and KEX2 gene 
products,  though they have been reported to operate in the 
Golgi complex (11, 30,  64).  To test for the involvement of 
these proteases, a kex/mutant was crossed to a kex2 mutant 
(BJ3369  x  BJ3368),  and tetrads were dissected.  The KEX 
genotype  had  no  effect  on  protease  B  activity  (data  not 
shown).  Furthermore,  only mature PrB accumulated in all 
of these strains, regardless of the KEXgenotype  (45; data not 
shown).  Curiously,  a  single gene that affected the  level of 
protease  B  and  protease  A  expression  segregated  in  this 
cross. However, this gene (named PEP22) was tightly linked 
to the ADE2 locus,  which  is not linked to either KEX1 or 
KEX2 (48). 
Novel PrB Processing Intermediate in a prbl Mutant 
In an attempt to identify a stable nonsense fragment of PrB, 
we screened immunoblots of protein extracts from our col- 
lection of 125 prbl mutants with the affinity-purified antibod- 
ies to the PrB peptide; such a stable nonsense fragment could 
be used to demonstrate which end of PrB is processed by 
protease A  (21,  68).  None of the prbl mutants synthesized 
a stable PrB nonsense fragment, but one of them, BJ52, did 
contain an interesting protease B species. This mutant accu- 
mulated some mature-size PrB as well as a 37-kD protein that 
cross-reacted with the  antibodies to the PrB peptide (Fig. 
11). When BJ52 was crossed to a pep4 mutant (BJ3496),  it 
was observed that thepep4 mutation was epistatic to theprbl 
mutation, because the 40-kD species was the only one pres- 
ent in thepep4prbl mutant (Fig.  11). The simplest explana- 
tion for these results is that there is a processing intermediate 
between the 40-kD zymogen and the 31-kD mature forms of 
PrB. The mutation in BJ52 does not interfere with the pro- 
tease A catalyzed processing step, but reduces the rate of the 
subsequent one. 
Protease B in prb2, prb3, and prb4 Mutants 
The prb2-prb4 mutants were identified in this laboratory in 
the same mutageneses that generated the prbl mutants (68). 
The prb2  and prb3 mutants  were reported  to be  Prb  + on 
yeast extract peptone glycerol (YEPG), but Prb- on YEPD. 
The prb4 mutants were reported to take four times as long 
as PRB strains to develop a  halo in the HPA test (68).  All 
of the  available  mutants  in  these  three  complementation 
groups were tested by the immunoblot technique, using pro- 
tein extracts from cells that had been allowed to grow to sta- 
tionary phase in liquid YEPD medium. Of the two prb2 mu- 
tants, one grew too poorly to work with, and one proved to 
be a prbl mutant.  Most of the prb3 mutants accumulated a 
normal amount of mature PrB under these conditions,  but 
three of them accumulated far less PrB than the PRB strain 
(BJII9, BJI21, and BJ126).  Protein extracts from the three 
available prb4 mutants were also analyzed on immunoblots. 
All three were completely lacking in PrB protein. Therefore, 
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Figure 12. Summary of PrB maturation pathway. This figure is ex- 
plained fully in the discussion.  N and C represent the amino and 
carboxy termini of the primary translation product. The horizontal 
lines represent the polypeptide backbone drawn to scale. Open ar- 
rows signify an interorganelle translocation step; closed arrows sig- 
nify an intraorganelle processing step. Gene names are placed so 
as to indicate which PrB intermediate accumulates in these mutants. 
The question mark signifies that we could not unambiguously deter- 
mine the nature of this intermediate.  The oval represents the hy- 
droxyl-linked glycosylation: no suggestion of the total amount is 
implied. The inverted Y represents the core of one Asn-linked car- 
bohydrate chain. The two circles attached to the Y represent elabo- 
rations of the core. The numbers to the right of the figure indicate 
the apparent molecular mass of each intermediate. 
neither the PRB3 nor the PRB4 gene products appear to be 
necessary for proper PrB maturation. 
Protease B in Immunoblots of Several pep Mutants 
Strains  bearing  a  mutation  at  the  PEP1-PEP15 loci  were 
tested for accumulation of PrB precursors. All ofthepep mu- 
tants were previously identified as being deficient in the ex- 
pression  of CpY  activity,  and  most pep  mutants  are  also 
deficient in the expression of other vacuolar hydrolase activi- 
ties (26).  Several of these mutants accumulate an inactive 
precursor form of CpY, proCpY, but except for PEP4, the 
function of the PEP gene products is not well understood 
(unpublished results). Protein extracts from one member or 
more of each of the pep1 through pep15 complementation 
groups were probed with antipeptide antibodies on a Western 
blot. Most of these mutants accumulated the 40- and/or the 
31-kD PrB species. In addition, four or five of these mutants, 
namely pep3,5,7,12, and maybe pep8, accumulated an addi- 
tional PrB species of ~37 kD. In none of these mutants did 
the 37-kD  species appear by itself; rather it was always ac- 
companied by the 40- and/or 31-kD species (data not shown). 
Thus, analysis of these mutants has failed to surface defects 
in the activity responsible for generating the mature amino 
terminus of PrB. 
Discussion 
Summary of Proposed Protease B Posttranslational 
Biosynthetic Pathway 
In a recent paper, we reported the PRB1 DNA sequence, the 
protease B amino-terminal protein sequence, and a model for 
the processing pathway for PrB  (47).  The DNA sequence 
predicted a 635 codon ORF that would encode a 70-kD poly- 
peptide with five potential sites for Ash-linked glycosylation. 
The mature protease was only 33 kD, however, and we knew 
that 280 codons preceded those that encoded the amino ter- 
minus of mature PrB. The only precursor to protease B that 
had been reported was a 42-kD kinetic precursor of identical 
relative molecular mass as a PrB species identified in apep4 
mutant (43,  44).  This 42-kD species had at least one Asn- 
linked side chain as judged by tunicamycin treatment. The 
mature  protease  did  not  have  any  tunicamycin-  or  Endo 
H-sensitive carbohydrate moieties (43,  44, 47), although it 
was clearly a glycoprotein (32, 47, 61). Also, a review of the 
literature revealed that yeast proteins were preferentially gly- 
cosylated at the Asn-Xaa-Thr consensus rather than the Asn- 
Xaa-Ser consensus  sequence  for Asn-linked  glycosylation 
(47). The PRB10RF encoded one of the N-X-T and four of 
the N-X-S sequences; the one containing Thr was the most 
carboxy-terminal of the five. Finally, the sequence similarity 
with the other proteases showed that all of the others in this 
group ended within one or two amino acids of each other, 
but the otherwise very similar protease B ran on for another 
50 or 60 amino acids before terminating (47).  From all of 
these data, we built a model for the processing pathway of 
PrB (47). In this model, preproPrB is synthesized as a 69.6- 
kD polypeptide. In an unspecified order, the preproPrB is 
glycosylated and proteolytically cleaved to yield an inactive, 
40-44-kD glycoprotein that has:  the same amino terminus 
as mature PrB; as much as 2.9 kD of non-Asn-linked carbo- 
hydrate on the mature portion of the enzyme; and 3.0 kD of 
Asn-linked glycosylation attached to the Asn at position 314 
(relative to the amino terminus of the mature protein). This 
zymogen form of PrB would be cleaved on the carboxy-ter- 
minal side, near to residue 293 where the homologous sub- 
tilisins are also terminated, by the PEP4  gene product, PrA 
(2, 66), to generate a 34-kD mature enzyme that contains 2.9 
kD of non-Asn-linked carbohydrate. 
Summary of the Actual Protease B Posttranslational 
Biosynthetic Pathway 
We have attempted to dissect the posttranslational biosyn- 
thetic pathway for PrB; the results are summarized in Fig. 
12.  PrB traverses the ER and Golgi complex en route to its 
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translation product, preproPrB, accumulates transiently be- 
fore being glycosylated and proteolytically processed. The 
order of  the intervening events in the PrB processing pathway 
is not entirely clear, but somehow the unglycosylated 76-kD 
form is transformed into the glycosylated 39-kD ER form. 
This ER form has both Asn-linked and non-Asn-linked (pre- 
sumably hydroxyl-linked) carbohydrate, and probably has 
the  same amino terminus as  the  mature PrB.  The much 
smaller proPrB enters the Golgi complex where a small addi- 
tion  is  made  to  the  carbohydrate  component.  The  fully 
glycosylated form of proPrB then undergoes two proteolytic 
cleavages  in  rapid  succession,  losing  its  Asn-linked side 
chain with the second of these clips, to give rise to the vacuo- 
lar mature PrB. Mature PrB contains no Asn-linked carbohy- 
drate, but does contain an undetermined amount of carbohy- 
drate, presumably hydroxyl linked. Whether or not a  PrB 
signal peptide is removed is not clear. The exact fate of the 
260-280-amino acid amino-terminal polypeptide is not yet 
clear, but it is possible that this polypeptide comigrates with 
proPrB (discussed below). 
PrB Processing Pathway  from Translation through the 
Golgi Complex 
Whether the full-length of preproPrB enters the ER is not 
clear from the results of these studies. The results presented 
in Figs. 7 and 9 show that a 76-kD preproPrB accumulates 
at the nonpermissive temperature in see61 and ~ec62 mu- 
tants, which are blocked at the cytoplasm-ER translocation 
step (10). A  PrB precursor of the same relative molecular 
mass  also  accumulates  transiently  in  pulse-labeled  SEC 
strains (Figs. 7, 8, and 9). The size of the 76-kD  species is 
not  affected by  tunicamycin,  an  inhibitor  of Asn-linked 
glycosylation (35),  in either sec or SEC strains (Fig. 9 and 
data not shown). 
In pulse-chase experiments, the sequence of events after 
the appearance of the unglycosylated 76-kD  species is not 
clear. In Fig. 8, PrB appears initially as a 76-kD protein that 
becomes slightly larger (2 kD?), and is then transformed into 
a glycosylated 39-kD protein without any smaller intermedi- 
ates. From the data in Fig. 9 it appears that the 76-kD precur- 
sor does chase into a larger 78-kD form in the absence, but 
not the presence, of tunicamycin (cf. lanes 1-3 of Fig. 9, A 
and B), as if the full-length 76-kD primary translation prod- 
uct enters the ER and receives some amount of glycosylation 
(Asn linked at least) before being processed into a smaller 
(39-kD) intermediate. These data suggest then, that glycosyl- 
ation is a posttranslational rather than cotranslational event- 
for protease B. However,  the apparent posttranslational gly- 
cosylation (and by implication, translocation) could be  a 
reflection of the location of the acceptor Asn at residue 314, 
41 residues shy of the carboxyl terminus, rather than a true 
indication of posttranslational translocation. If thg distance 
between the inner surface of the ER membrane and the pep- 
tidyl site in a ribosome is *70-amino acid residues, cotrans- 
lational translocation of the protein would still result in ter- 
mination of translation before glycosylation simply because 
the distance between the acceptor and the end of  the polypep- 
tide is substantially <70 residues. That the unglycosylated 
76-kD  species detected in pulse-chase experiments is the 
same size as the species that accumulates outside the ER in 
the sec61 and sec62 mutants is unexpected, however, if signal 
peptidase acts before completion of translation. If the 76-kD 
precursor chases into a 78-kD intermediate, then all of the 
76-kD  preproprotease B must enter the ER. 
One troublesome observation, however, is the 93-kD spe- 
cies seen in Fig. 9 B but not 9 C. (In Fig. 9, B and C the 
exact  same prbl-Al.6 strain  was  transformed with either 
YCp50::PRB1  or YCp50,  respectively; labeled in the same 
media on the same morning; extracted and immuneprecipi- 
tated at the same time; and fractionated on the same poly- 
acrylamide gel.) Furthermore, the 93-kD protein could have 
one Asn-linked side chain; the size of this species appeared 
to be affected by tunicamycin (smaller by "~3 kD). One must 
consider the possibility that preproprotease B undergoes ex- 
tensive hydroxyl-linked  glycosylation, like the low density li- 
poprotein receptor of mammalian cells (9, 59), before being 
processed to the 39-kD form. 
There are three objections to the hypothesis that protease 
B has a 93-kD intermediate, however. First and foremost, the 
kinetics of  appearance and disappearance for this putative in- 
termediate do not look quite right: it appears and disappears 
a little too late to be an intermediate between the 76- and 39- 
kD forms. Second, insofar as hydroxyl-linked glycosyl moi- 
eties in the ER of yeast are thought to consist of Man~ units 
(18),  ~100  serine or threonine residues would have to be 
glycosylated to account for an additional Mr of 16 kD. Even 
taking into account the aberrant migration of glycoproteins 
in polyacrylamide gels, wherein these proteins appear larger 
than they actually are (56), most or all of the 83 serine plus 
threonine residues of preproprotease  B  would have to be 
glycosylated with Man~ in order to account for this increase 
in size.  Third, a 93-kD band appears in the prblAL6 lane 
of Fig. 7 (lane 13). Fig. 7 does not provide a very good con- 
trol for Fig. 9, but still, it does weaken the possibility that 
the 93-kD protein is a PrB intermediate. 
The relative molecular mass of the primary translation 
product (76 kD) is somewhat larger than predicted from the 
deduced amino acid sequence (70 kD; 47).  This aberrant 
migration is also observed with the IPTG-induced ORF pro- 
tein (77  kD observed vs.  71  kD predicted).  This anomaly 
may result from the net charge of +12 on this protein, of 
which +11 is found in the first 280 amino acids. This high 
net charge and high charge density (111 of 280 residues) also 
makes us wonder whether this part of the protein passes 
through a membrane at all. 
No species intermediate in size between 76 and 39 kD was 
seen. The results with mutants having conditional ER defects 
combined with the pulse-chase experiments in Figs. 7, 8, and 
9, show that the 39-kD PrB species appears very early and 
is in the ER. Four secretory mutants that have conditional 
defects in  ER functions, namely sec18, sec11, sec53, and 
sec59, were tested under nonpermissive conditions to deter- 
mine what form(s) of protease B antigens accumulated. The 
sec18 mutation confers a conditional defect in translocation 
of  proteins from the ER to the Golgi complex; under nonper- 
missive conditions sec18 mutants accumulate an ER precur- 
sor form of CpY (known as "pl') and secreted invertase (13). 
The 39-kD kinetic intermediate comigrated with a PrB anti- 
gen found in a sec18 mutant under nonpermissive conditions 
(Figs. 7, 8, and 9), thereby showing this kinetic intermediate 
to be an ER species.  The SEC11 gene product is believed to 
be part of a yeast signal peptidase complex. Signal peptidase 
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(3,  14),  and the SEC11 sequence predicts a protein that is 
similar in size and pI to the smallest of  the subunits described 
by Baker and Lively (3, 6). Mutants lacking the SEC11 gene 
product fail to cleave the signal peptide of CpY and secreted 
invertase, and have slowed kinetics of secretion for these two 
proteins (6). Other proteins are affected to different extents 
in the sec11 mutant:  some proteins are not affected at all, 
others are completely blocked in the ER, and still others are 
slowed in their kinetics of secretion (50). The secll mutant 
accumulates a 39-kD form of PrB that comigrates with that 
found in the sec18  mutant (Fig. 5); we have not tried to assess 
the kinetics of PrB secretion in the see11 mutant. The SEC53 
and SEC59 gene products at one time were believed to be 
necessary for entry into the ER, but now their function is un- 
clear (15).  The sec53 and sec59 mutants are conditionally 
defective in an unknown, early ER function and accumulate 
an aberrant, underglycosylated form of CpY and secreted in- 
vertase (15). Under nonpermissive conditions, both of these 
mutants accumulated two PrB-related proteins, one of which 
resembled mature PrB, and the other of which resembled un- 
derglycosylated proPrB (Fig. 6, sec53 not shown). Because 
the  antibodies  used  in  the sec53/sec59  experiments react 
with epitopes along the entire length ofpreproPrB, we do not 
know whether either of  the two PrB species was derived from 
the amino-terminal half of the full-length protein. It seems 
possible that the smaller of these would be derived from the 
amino-terminal half, because one would not expect mature 
PrB to accumulate in mutants that are blocked at an ER step 
of secretion. 
In kinetic experiments, the 39-kD ER form of PrB chased 
to a 40-kD species (Figs. 7, 8, and 9). This 40-kD species 
comigrated with the PrB zymogen found in pep4 mutants 
(Figs. 7 and 9), as well as that found in a sec14 mutant (not 
shown). Thepep4 mutation leads to an accumulation of inac- 
tive precursors for most soluble vacuolar hydrolases (21). 
The sec14 mutation confers a conditional defect in translo- 
cation of secretory proteins from the Golgi complex (13). 
Therefore, processing of the PrB zymogen to mature PrB oc- 
curs either in a late Golgi compartment or in the vacuole, as 
it does for CpY (13). 
Vacuolar Processing Steps in PrB Maturation 
In kinetic experiments, the 40-kD proPrB is processed into 
a 37-kD intermediate that retains an Asn-linked side chain, 
and subsequently into 31-kD mature PrB (Fig. 9, A and B). 
The PEP4 gene product,  PrA (2,  66),  is required for the 
40 ~  37-kD processing step, as this step does not normally 
occur in pep4 mutants (e.g., Fig. 2). The gene products of 
several other PEP genes were required for one or both steps 
of vacuolar processing of PrB, but there is no evidence that 
any of these genes encodes a protease. 
The short-lived 37-kD kinetic intermediate has probably 
been observed in other experiments as well. During an at- 
tempted purification of proPrB from a pep4 mutant, the 40- 
kD zymogen species started degrading into a 37-kD form and 
then rapidly degraded into mature PrB in vitro (45). The 37- 
ld) kinetic intermediate is also approximately the same size 
as a PrB antigen found in several mutants. Theprbl-628 mu- 
tant (BJ52) accumulated a 37-kD PrB protein that was not 
visible in prbl-628 pep4 mutants (Fig.  11). The epistasis of 
the pep4 mutation indicates that the prbl-628 allele encodes 
a PrB protein that cannot undergo or only slowly undergoes 
the 37 --- 31-kD processing step. Strains that are mutant in 
the pep3, pep5, pepT, pep12, and possibly pep8 loci also ac- 
cumulated a  37-kD  PrB species.  It is possible that PrA is 
responsible for the final processing step and these other pep 
mutants accumulate the 37-kD PrB form as a consequence of 
their PrA deficiency, but it is also possible that the accumula- 
tion of  the 37-kD species is a clue to some other physiological 
defect shared by this subset of  pep mutants. This same subset 
of pep mutants has been reported to share other phenotypes 
not common to all pep mutants (27). 
The relatively short-lived 37-kD intermediate is approxi- 
mately the same size as the PrB zymogen found in tunica- 
mycin-treated cells. This is simply a coincidence, because 
the size of the 37-kD kinetic intermediate was itself sensitive 
to tunicamycin treatment (Fig. 9). A 37-kD form of PrB also 
accumulated in the sec53 and sec59 mutants. Again, we do 
not think that this is the same as the 37-kD kinetic intermedi- 
ate  because these two sec, mutants  accumulate ER mem- 
branes and aberrant, underglycosylated ER forms of other 
proteins (13, 15). 
Identity of  Proteases Involved in PrB Processing 
There are at least three proteolytic processing steps neces- 
sary for the maturation of protease B: 76 (78 kD) ~  39 kD, 
40 ~  37 kD, and 37 ~  31 kD.  (At present there is no clear 
evidence pertaining to a signal peptide cleavage event.) The 
penultimate processing step, conversion of 40 kD to 37 kD, 
must be mediated by the PEP4 gene product, PrA (2, 66), 
because it does not occur inpep4 mutants. Thatprcl mutants 
are Prb  ÷ excludes CpY as the protease responsible for the 
final maturation event; there are no data on whether PrA, 
PrB, or another protease mediates this final step. The data 
exclude the SEC11 gene product (part of the signal peptidase 
complex; 6), the KEX/-encoded carboxypeptidase, and the 
KEX2-encoded endoprotease as being responsible for the ini- 
tial 76 (78 kD) --- 39 kD cleavage. It is interesting to note that 
a two codon change at the amino terminus of mature PrB 
(Glu-Phe changed to Asp-Leu; data not shown) still results 
in prbl complementation. Presumably, the protease respon- 
sible for the cleavage in the ER has some flexibility in the 
target sequences whose cleavage it catalyzes. 
PrA Cleaves the Carboxy-terminal End of 
Proprotease B 
Based on discrepancies in predicted and observed molecular 
masses for proPrB and mature PrB, we postulated that the 
PEP4-mediated processing step occurs at the carboxyl end 
of proPrB (47). Evidence supporting this hypothesis is pre- 
sented in Fig. 10. Both proPrB and mature PrB share a com- 
mon semistable degradation product of the same size that is 
recognized by antibodies against the amino terminus of ma- 
ture PrB. This suggests that these two forms share a common 
amino terminus,  and that the subsequent processing steps 
must occur at the carboxyl end. Furthermore, the identifica- 
tion of a penultimate processing step that removes 3 kD but 
yields a product that contains an Asn-linked side chain re- 
quires that there be at least 18-20 amino acids distal to the 
one Asn-linked side chain on proPrB. This presents no prob- 
lem for carboxy-terminal processing, as there are 41 amino 
acids distal to the potential glycosylation site.  However, for 
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would have to be at, or upstream of, the Glu at position -86 
relative to the amino terminus of mature Prb, since the poten- 
tial tripeptide glycosylation acceptor is at position  -68.  If 
this were true, it would require that the 635-amino acid, 76- 
kD precursor consist of two parts: an amino-terminal half of 
194 amino acids that accounted for 39 kD, and a carboxy- 
terminal half of 441  amino acids that only accounted for 37 
kD (unglycosylated molecular masses). Clearly the data are 
in agreement with carboxy-terminal processing, and not with 
amino-terminal processing, by PrA. 
Fate of the Amino-terminal 280 Amino Acids of 
Preproprotease B 
The fate of the 280-amino acid amino-terminal polypeptide 
is unclear. The polypeptide was not apparent in the experi- 
ments represented by Figs. 3, 4, 5, and 7, where one would 
expect to see it. Part of the answer could be in Fig. 9. In Fig. 
9 A, it appears that the tunicamycin treatment was somewhat 
ineffective, as a significant amount of 39-40-kD PrB is pres- 
ent. However, Fig. 9 D, which represents the CPY found in 
the very same extracts, suggests that the tunicamycin treat- 
ment  was  effective.  Furthermore,  the  relative  molecular 
mass of the secl8 PrB species (39 kD) is just about one-half 
the relative molecular mass of preproPrB (76 kD). Perhaps 
the amino-terminal polypeptide initially comigrates with the 
secl8 form of PrB, and is later degraded or secreted. A corol- 
lary of this hypothesis requires that the amino-terminal poly- 
peptide is not glycosylated at its one Asn-linked glycosyla- 
tion consensus  sequence (Asn-Leu-Ser at  -68).  We have 
constructed  a  fusion  between  the  anthranilate  synthetase 
(TrpE) protein of E. coli and the amino-terminal portion of 
PrB. We have purified this fusion protein and are using it to 
affinity purify a subset of antibodies from the 77-kD ORF an- 
tiserum in order to address this problem more fully. 
Glycosylation  of PrB and Its Precursors 
Glycosylation in yeast has recently been reviewed (33,  55, 
58).  Transfer from dolichol carriers of Glc3MangGlcNAc2 
to asparagine residues, as well as Man~ to serine and threo- 
nine residues, is known to occur in the ER (13, 18). The Asn- 
linked side chains are quickly trimmed to MangGlcNAc2 (in 
GLS1 strains), and then to the MansGlcNAc2  form that ac- 
cumulates in secl8-blocked cells (12).  The hydroxyl-linked 
side chains accumulate primarily as the Man~ form during 
the secl8 block (18). Once secretory proteins reach the Golgi 
compartment, their carbohydrate moieties are elaborated. To 
the Asn-linked core are added 0-7 Man~ units for a total of 
8-15 mannose residues per chain (60). Primarily for exter- 
nally secreted proteins, the "core" is further elaborated in the 
Golgi  compartment  by  adding  outer  chain  segments  of 
Mans-j4 up to totals as high as  150 residues per side chain 
(60). To the hydroxyl-linked Mant units, 0-3 mannose resi- 
dues are added in the Golgi compartment (18). 
PreproPrB  and  proPrB have both  Asn-linked  and  non- 
Asn-linked  carbohydrate; mature  PrB only has  non-Asn- 
linked carbohydrate. Fig. 9 B shows that one or more Asn- 
linked side chains are added to the 76-kD preproPrB in the 
ER. One Asn-linked chain is retained on all the processing 
intermediates, but no Asn-linked carbohydrate is present on 
the 31-kD mature form (Figs.  1, 2, 4, and 9). Figs. 3 and 4 
demonstrate that only one or two (probably two) mannose 
units are added to the Mar~GlcNAc2  (see18) chain. There- 
fore, the Asn-linked moiety on proPrB inpep4 mutants exists 
as MantoGlcNAc2.  Figs.  3 and 4  also demonstrate that ei- 
ther zero or one (probably zero) mannose units are added to 
the sum of the non-Asn-linked carbohydrate present on the 
39-kD  intermediate.  Therefore, any  non-Asn-linked  (pre- 
sumably hydroxyl-linked) side chains on proPrB or mature 
PrB must exist as Man~ units.  This also is consistent with 
the lack of effect of the mnnl mutation on proPrB or mature 
PrB. Mature PrB is assumed to have hydroxyl-linked carbo- 
hydrate by the following argument. Previously, we reported 
a PrB purification scheme that used affinity chromatography 
over a Con A-Sepharose column and elution with o~-methyl- 
mannoside (47).  This approach was  based on two earlier 
reports claiming that mature PrB contained 9 % (32) and "no 
greater than  0.5%" carbohydrate (61).  Mature protease B 
clearly has some form of mannose-containing carbohydrate, 
and since it cannot be Asn linked (this work; 43), we assume 
that it is hydroxyl linked. 
Relative Half-Times for Maturation of Protease B and 
Carboxypeptidase  Y 
Much work has been devoted to studying CPY as a model 
vacuolar protein. The transit and processing times for CPY 
have been well characterized (reviewed in reference 28). The 
transit time for CPY at 25°C was similar to that for PrB (Fig. 
9). Fig. 9 also provides a clear depiction that CpY is probably 
cotranslationally modified and PrB is definitely posttransla- 
tionally modified. 
Studies of Vacuolar Targeting of Protease B 
As an outgrowth of investigations into the secretory process 
in yeast, there has been a great deal of interest in identifying 
both the gene products involved in protein sorting and the 
signals used by the cell for this sorting.  Two groups have 
reported having mutants that are defective in the sorting of 
yeast vacuolar proteins (5, 53). Because it is known that yeast 
cells do not use mannose-6-phosphate for a vacuolar sorting 
signal the way mammalian cells do for lysosomal proteins 
(57), it is likely that the sorting signal is encoded in the pri- 
mary or higher order sequence of the targeted protein. (For 
that matter yeast do not even make the same type of man- 
nose-6-phosphate units that mammalian cells do: yeast has 
an exposed R-Man-P-Man whereas animal cells have an ex- 
posed R-Man-P [19; reviewed in reference 63].) Through the 
use of a series ofprcl mutants (62), and CpY-invertase  (25) 
and PrA-invertase (31) protein fusions, defined segments of 
the propeptide sequences of proCpY and proPrA have been 
identified that are both necessary and sufficient for localiza- 
tion of these proteins to the vacuole. 
The organization of the PRB10RF does not resemble that 
of the PEP4  and PRC10RFs, and the signals for PrB sorting 
do not appear to reside in homologous positions either. Re- 
call that the processing of the 76-kD preproPrB to the 39-kD 
form occurs very rapidly in the ER, and that the first 280 
amino acids of  preproPrB are cleaved before it leaves the ER. 
The obvious conclusion to be drawn from this is that either 
the first 280 amino acids of preproPrB do not contribute to 
the sorting signal, or, the sorting decision for protease B oc- 
curs very early in the ER. A third possibility is that, although 
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uct polypeptides remain attached,  possibly through  a disul- 
fide bond, and that PrB is targeted by its piggyback prepro 
region. There is no evidence in favor of the sorting decision 
occurring in the ER. With the possible exception of PEP7 
(Garlow, S., and E. Jones, Carnegie Mellon University,  un- 
published data),  there are no genes known that affect the 
secretion  or processing  of vacuolar  proteins before entry 
into the vacuole, and yet fail to affect externally secreted pro- 
teins. In other words, both sets of secretory proteins seem 
to share the same processing machinery from ER transloca- 
tion through  to the late Golgi compartment (57). 
The structure of PrB and its precursors raise several ques- 
tions about protein processing and secretion in yeast; further 
studies of this protein should provide fresh insight into these 
processes.  PrB may become a model protein for studies of 
translational-translocational interactions in yeast. The large 
shift in the relative molecular mass of PrB that occurs in the 
ER,  as opposed to the relatively  small  shift observed for 
other secretory proteins, makes this protein a useful probe 
in studies of ER function. Because proPrB has only one Asn- 
linked carbohydrate  side chain,  it is a better  substrate  for 
studying subtle aspects of this type of glycosylation than pro- 
teins having multiple side chains. Because mature PrB is rel- 
atively  small  and  has  only  non-Asn-linked  carbohydrate, 
and also because its structural gene has been cloned and se- 
quenced, it should be a useful substrate  for studies of non- 
Asn-linked  glycosylation.  Finally,  further  studies  on  the 
processing  of PrB precursors may  identify two new yeast 
processing proteases, one in the ER and one in the vacuole. 
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